The Narcotic Drug and Opioid Peptide Basic Research Project enters its 31st year with continued vigor and enthusiasm. Several aspects of the Center are logical extensions of efforts of earlier years; other aspects represent entirely new areas of interest. Included in the former category are studies that refine and analyze the pharmacological effects of opioids in the rhesus monkey. Our research on the analgesic, respiratory, and reinforcing effects of opioids will continue into new avenues. In addition, studies using newly developed analgesia are included that may provide evidence for novel, additional pathways through which opioids can provide therapeutic action against pain and inflammatory processes. Similarly, studies of the reinforcing effects of opioids will be extended to new procedures that may provide evidence of increasing reinforcing effects of opioids during withdrawal and eventually, protracted withdrawal. The drug discovery program will continue to evaluate the in vivo and in vitro effects of opioids in rodents and in vivo effects of opioids in nonhuman primates. One objective of this aspect of the Center is to determine the mechanism by which buprenorphine exerts its novel actions that make it an extremely interesting pharmacotherapy for opioid abuse. The work of the human behavioral pharmacology laboratory continues on the focus of the evaluation of buprenorphine as a pharmacotherapy and makes direct comparison to methadone in some its pharmacology. Studies utilizing labeled carfentanil in PET imaging studies will compare buprenorphine's binding to central mu-receptors with its antagonism of hydromorphone's pharmacological effects. A new area of research is a major chemical venture toward the development of radiolabeled PET ligands specific to opioid function in pharmacologicical, physiological, and pathophysiological Conditions in primates and humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA000254-35
Application #
7091645
Study Section
Special Emphasis Panel (ZDA1-RXL-E (23))
Program Officer
Thomas, David A
Project Start
1997-07-15
Project End
2007-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
35
Fiscal Year
2006
Total Cost
$1,153,664
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Reilly, Mark P; Berndt, Sonja I; Woods, James H (2016) On the nature of directed behavior to drug-associated light cues in rhesus monkeys (Macaca mulatta). Behav Anal (Wash D C) 16:200-209
Woodcock, Eric A; Lundahl, Leslie H; Stoltman, Jonathan J K et al. (2015) Progression to regular heroin use: examination of patterns, predictors, and consequences. Addict Behav 45:287-93
Stoltman, Jonathan J K; Woodcock, Eric A; Lister, Jamey J et al. (2015) Exploration of the telescoping effect among not-in-treatment, intensive heroin-using research volunteers. Drug Alcohol Depend 148:217-20
Mancha, Brent Edward; Hulbert, Alicia; Latimer, William W (2012) A latent class analysis of alcohol abuse and dependence symptoms among Puerto Rican youth. Subst Use Misuse 47:429-41
Moynihan, Humphrey A; Derrick, Ian; Broadbear, Jillian H et al. (2012) Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible ? opioid receptor antagonist effects. J Med Chem 55:9868-74
Mancha, Brent E; Rojas, Vanessa C; Latimer, William W (2012) Alcohol use, alcohol problems, and problem behavior engagement among students at two schools in northern Mexico. Alcohol 46:695-701
Pichika, Rama; Jewett, Douglas M; Sherman, Philip S et al. (2010) Synthesis and in vivo brain distribution of carbon-11-labeled ?-opioid receptor agonists. Nucl Med Biol 37:989-96
Cooper, Ziva D; Shi, Yong-Gong; Woods, James H (2010) Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology (Berl) 212:369-78
Ko, Mei-Chuan; Woods, James H; Fantegrossi, William E et al. (2009) Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34:2088-96
Nieland, Nick P R; Rennison, David; Broadbear, Jillian H et al. (2009) 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists. J Med Chem 52:6926-30

Showing the most recent 10 out of 36 publications